title: Results of peripheral laser photocoagulation in pars planitis.
abstract: OBJECTIVE
  To determine the effect of peripheral retinal laser photocoagulation (PLP) on visual acuity, intraocular inflammation, and other ocular findings, including retinal neovascularization in eyes with pars planitis.
  
  
  METHODS
  A retrospective chart review of eyes with pars planitis that had undergone PLP.
  
  
  RESULTS
  Twenty-two eyes in 17 patients with pars planitis had undergone treatment with PLP at 2 centers. The mean age at the time of treatment was 19.3 years. Following treatment, mean follow-up was 16.3 months (range, 6 to 37 months). Mean visual acuity was 20/60 preoperatively and 20/50 postoperatively. This level of improvement was not statistically significant (P > .10), but there was a statistically significant decrease in the use of corticosteroids between the preoperative examination and the last postoperative examination (86% versus 27%, P < .05). There was also a statistically significant decrease in vitritis at the last follow-up (P = .0008) and a decrease in neovascularization of the vitreous base (P = .03) and in clinically apparent cystoid macular edema (P = .02). Epiretinal membranes were noted in 23% of eyes preoperatively and in 45% of eyes postoperatively. Only one of these epiretinal membranes was considered to be visually significant. One eye developed a tonic dilated pupil, which slowly improved.
  
  
  CONCLUSIONS
  Although the long-term natural history of clinical findings in pars planitis is not well documented, PLP appears to decrease the need for corticosteroids while stabilizing visual acuity. It also appears to decrease vitreous inflammation. PLP has few complications and should be considered in patients with pars planitis who are unresponsive or have adverse reactions to corticosteroids.
authors.affiliation: Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Pulido
authors.forename: W F
authors.initials: WF
authors.lastname: Mieler
authors.forename: D
authors.initials: D
authors.lastname: Walton
authors.forename: E
authors.initials: E
authors.lastname: Kuhn
authors.forename: E
authors.initials: E
authors.lastname: Postel
authors.forename: A
authors.initials: A
authors.lastname: Hartz
authors.forename: L M
authors.initials: LM
authors.lastname: Jampol
authors.forename: D V
authors.initials: DV
authors.lastname: Weinberg
authors.forename: S
authors.initials: S
authors.lastname: Logani
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D002648:Child; D009877:Endophthalmitis / Q000601:surgery; D005260:Female; D006801:Humans; D017075:Laser Coagulation; D008269:Macular Edema / Q000601:surgery; D008297:Male; D009389:Neovascularization, Pathologic / Q000601:surgery; D015868:Pars Planitis / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D011184:Postoperative Period; D012189:Retrospective Studies; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body / Q000098:blood supply
chemical_list: D000305:Adrenal Cortex Hormones